EUVIMED · CrossrefZeitschrift
Clinical Cancer Research
ISSN 1078-0432 · American Association for Cancer Research (AACR)
Neueste Artikel
An Act of DeFianCe: Targeting DKK1 in Metastatic Colorectal Cancer
Second- and Third-Line Outcomes after Selective RET Inhibitor Failure in RET Fusion-Positive Metastatic Lung Cancer: A Real-World Analysis from the RET-MAP Registry
Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin
Dual VEGF and PD-(L)1 Blockade: Facts and Hopes
Targeting DHFR to suppress one-carbon metabolism and enhance radiation sensitivity in patients with NRF2-active head and neck squamous cell carcinoma
SPROUT Guidelines for Molecular Profiling for Children with Solid Tumors: A Consensus Recommendation from the American Association for Cancer Research
Anti-TNFR2 Antibody BI-1808 Induces Tumor Regression and Antitumor T-cell Immunity through Treg and Myeloid Cell Modulation in Patients with Solid Tumors
Palbociclib, Fulvestrant, Trastuzumab, and Pyrotinib for Patients with Advanced Breast Cancer with Brain Metastases: A Prospective Multicenter Phase 2 Trial
Prevalence and Actionability of MTAP Loss in Driver Oncogene-Positive and Oncogene-Negative Lung Cancer
BRCA1 at the Crossroads of Genome Stability, Mitochondrial Homeostasis, and Tumor Immunity
Kinetics of Re-differentiation with Short-Course Dabrafenib and Trametinib in Patients with Radioiodine-Refractory Thyroid Cancer
Phase I Trial and Biomarker Analysis of Buparlisib with Weekly Cisplatin and Radiotherapy in High-risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
Integrated multi-omics reveals longitudinal metabolic dynamics and reprogramming in bladder cancer
Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK -Altered Advanced Solid Tumors: A Phase II TACKLE Trial (NCCH1712/MK003)
Multiomics Analysis of Malignant Pleural Mesothelioma Reveals the Immunological Microenvironment Associated with MTAP Loss and Immunotherapy Outcomes
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor-Positive and Triple-Negative Breast Cancer
Comparison of PSMA- and CD70-targeted PET/CT in The Diagnosis of Renal Cell Carcinoma: A Retrospective Cohort and Prospective Head-to-head Study
Differential Impact of Tumor-Derived ESR1 Mutations on Elacestrant Benefit in Metastatic Breast Cancer
A Phase II Study of Nivolumab and Ipilimumab with Radiotherapy in Patients with Metastatic, Microsatellite-Stable Colorectal Cancer
FIND: A Phase II Study to Evaluate the Efficacy and Safety of Erdafitinib in FGFR -Altered NSCLC
Complement-driven NETosis mediates immunotherapy resistance in STK11 -mutant lung adenocarcinoma
Multi-institutional Patient-Level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence in Prostate Cancer
Ultrasensitive ctDNA Assay Lowers the Detection Floor in Esophageal Cancer
Adrenergic Regulation of Cancer Immunity
ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L
Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
A Phase II Trial of Pembrolizumab plus Granulocyte–Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer
A Phase I First-Time-in-Human, Open-label Study of Nelistotug Administered to Patients with Advanced Solid Tumors
Neoadjuvant Chemoimmunotherapy Improves Response Rates in Head and Neck Cancer
EUVIMED